8/3/24, 9:40

Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random...

## Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Randomized Controlled Trial Protocol: Case report form

Fundación Santa Fe de Bogotá, Department of Critical Medicine and Intensive Care

1.	Identification of the patient in the study
2.	Group assigned by randomization
	Mark only one oval.
	EaDyn (intervention)
	MAP (control)
3.	Inclusion criteria (check all those applying)
	Check all that apply.
	Patient over 18 years old
	Septic shock patients defined according to the third international consensus of sepsis as patients who clinically present vasopressor support requirement to maintain a MAP $\geq$ 65 mmHg or a lactate level $\geq$ 2 mmol/L in the absence of hypovolemia
	SOFA score of ≥ 4 points
	Patients requiring vasopressor support for a period of 4 hours or more

8/3/24, 9:40 Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random...

**Exclusion criteria (check all applicable)** 

Pregnant women  Hemodynamically unstable cardiac arrhythmias  Treetment with another vacapragaer other than peradropoline or ignotropic suppo			
		Treatment with another vasopressor other than noradrenaline or ionotropic support requirement	
Patients with right heart failure Patients diagnosed with cirrhosis of the liver Patients who have received renal and/or hepatic transplantation			
		Patients Criteria	with a high probability of mortality in 24 hours defined according to medica
		interia	
Age (years			
Weight (Kç	)		
Weight (Koฺ	)		
Weight (Κ <u></u> ξ			
	according to ICD-10		
Weight (Kç			

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random		
8.	Intensive inpatient care unit		
	Mark only one oval.		
	Surgical unit		
	Neurological unit		
	Sepsis / respiratory unit		
	Cardiovascular		
	Burn unit		
9.	SOFA score at start of vasopressor support		
10.	Dose of noradrenaline at study inclusion (mcg/kg/min)		
11.	Total, noradrenaline infusion duration (hours)		
12.	Total, of noradrenaline administered (mg)		
13.	Total, of liquids administered (mL/kg/h)		
13.	Total, of liquids administered (mL/kg/h)		

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random
14.	Hypotension during weaning (MAP < 50 mmHg)
	Mark only one oval.
	Yes
	No
15.	Death
	Mark only one oval.
	Yes
	No
16.	Stay in ICU (time when the patient is without vasopressor and ventilatory support, days)
17.	Stay in hospital (time at which doctor gives the order in the medical history of discharge, days)
Vai	riables to be taken daily
DAY	′1
18.	Duration of NE (h)
19.	Dose of NE (mg)

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random	
20.	Administered liquids (mL)	
21.	Diuresis (mL)	
22.	Balance of liquids (mL)	
23.	Blood products	
	ariables to be taken daily	
24.	Duration of NE (h)	
25.	Dose of NE (mg)	
26.	Administered liquids (mL)	
27.	Diuresis (mL)	

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random	
28.	Balance of liquids (mL)	
29.	Blood products	
Va	riables to be taken daily	
DA	Y 3	
30.	Duration of NE (h)	
31.	Dose of NE (mg)	
32.	Administered liquids (mL)	
33.	Diuresis (mL)	
34.	Balance of liquids (mL)	
35.	Blood products	

8/3/24, 9:40 Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random...

## Variables to be taken daily DAY 4 **Duration of NE (h)** 36. 37. Dose of NE (mg) 38. Administered liquids (mL) Diuresis (mL) 39. 40. Balance of liquids (mL) **Blood products** 41. Variables to be taken daily

DAY 5

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random.	
42.	Duration of NE (h)	_
43.	Dose of NE (mg)	
44.	Administered liquids (mL)	
45.	Diuresis (mL)	
46.	Balance of liquids (mL)	
47.	Blood products	
<b>Va</b> . DA	<b>riables to be taken daily</b>	
48.	Duration of NE (h)	
49.	Dose of NE (mg)	
		_

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random	
50.	Administered liquids (mL)	
51.	Diuresis (mL)	
52.	Balance of liquids (mL)	
53.	Blood products	
	ariables to be taken daily	
<i>DA</i> 54.	AY 7  Duration of NE (h)	
55.	Dose of NE (mg)	
56.	Administered liquids (mL)	
57.	Diuresis (mL)	

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random.	
58.	Balance of liquids (mL)	_
59.	Blood products	
Va	riables to be taken daily	
DA	Y 8	
60.	Duration of NE (h)	
61.	Dose of NE (mg)	
62.	Administered liquids (mL)	
63.	Diuresis (mL)	
64.	Balance of liquids (mL)	
65.	Blood products	

8/3/24, 9:40 Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random...

	ariables to be taken daily	
DA	AY 9	
66.	Duration of NE (h)	
67.	Dose of NE (mg)	
68.	Administered liquids (mL)	
69.	Diuresis (mL)	
70.	Balance of liquids (mL)	
71.	Blood products	
	ariables to be taken daily	
DA	AY 10	

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random
72.	Duration of NE (h)
73.	Dose of NE (mg)
74.	Administered liquids (mL)
75.	Diuresis (mL)
76.	Balance of liquids (mL)
77.	Blood products  Mark only one oval.  Yes
	No  ariables that change in the three points of measurment the beginning of administration of Noradrenaline
78.	SOFA score

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety d	uring Vasopressor Support Weaning in Septic Shock Patients: A Random
79.	Heart rate	-
80.	MAP	
81.	Central venous pressure	
82.	Cardiac index (CI)	
83.	Saline solution administered (mL)	
84.	Albumin (mL)	
85.	Blood products  Mark only one oval.  Yes  No	
86.	Albumin (mL)	

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random.
87.	Dose of noradrenaline (mg)
88.	Lactate (mmol/L)
89.	Venous saturation
90.	Diuresis (mL)
	the beginning of the weaning of vasopressor support
91.	SOFA score
92.	Heart rate
93.	MAP
94.	Central venous pressure

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety do	ring Vasopressor Support Weaning in Septic Shock Patients: A Random
95.	Cardiac index (CI)	
96.	Saline solution administered (mL)	
97.	Albumin (mL)	
98.	Blood products  Mark only one oval.	
99.	Albumin (mL)	
100.	Dose of noradrenaline (mg)	_
101.	Lactate (mmol/L)	
102.	Venous saturation	
		-

BMJ Open

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety du	ing Vasopressor Support Weaning in Septic Shock Patients: A Random
103.	Diuresis (mL)	
Var	iables that change in the three points of	measurment
At th	ne end of weaning vasopressor support	
104.	SOFA score	
105.	Heart rate	
106.	MAP	
107.	Central venous pressure	
108.	Cardiac index (CI)	
109.	Saline solution administered (mL)	
110.	Albumin (mL)	

8/3/24, 9:40	Evaluation of Dynamic Arterial Elastance Efficacy and Safety during Vasopressor Support Weaning in Septic Shock Patients: A Random
111.	Blood products
	Mark only one oval.
	Yes
	◯ No
112.	Albumin (mL)
113.	Dose of noradrenaline (mg)
114.	Lactate (mmol/L)
115.	Venous saturation
116.	Diuresis (mL)

This content is neither created nor endorsed by Google.

## Google Forms